Skip to main content

Table 1 Demographic data of study subjects (n = 99)

From: Blood lipid profiles and peripheral blood mononuclear cell cholesterol metabolism gene expression in patients with and without methotrexate treatment

Characteristics Reference value/range Non-MTX users (n = 32) MTX users (n = 67) Pvaluea
Male/female   8/24 10/57  
Age, years   53.0 (49.0 to 58.0) 53.0 (50.3 to 57.0) 0.979
BMI, kg/m2 18.5-23.9 22.8 (21.6 to 24.4) 21.8 (21.6 to 23.5) 0.725
WBC count, cells/mm3 5,000-10,000 6,400 (5,536 to 6,844) 5,900 (5,980 to 6,900) 0.745
Hb, g/dl 12-16 12.9 (11.7 to 13.2) 12.6 (12.2 to 12.9) 0.765
Serum creatinine, mg/dl <1.4 0.90 (0.87 to 1.13) 0.80 (0.79 to 0.87) 0.222
ALT, IU/L 0-40 15.0 (15.0 to 29.1) 16.0 (15.3 to 20.0) 0.976
CRP (mg/dL) <0.3 0.40 (0.53 to 1.65) 0.22 (0.52 to 1.75) 0.161
Systolic BP, mmHg <140 130.0 (123.4 to 133.8) 129.0 (114.7 to 142.2) 0.634
Diastolic BP, mmHg <90 80.0 (76.2 to 82.3) 79.0 (65.8 to 92.7) 0.732
Disease duration, years   14.1 (11.5 to 16.8) 12.0 (11.3 to 15.0) 0.456
Disease activity, HAQ   0.187 (0.11 to 0.80) 0.125 (0.20 to 0.49) 0.917
Physical activity, h/week   0.00 (0.37 to 3.85) 0.50 (1.14 to 2.41) 0.552
Methotrexate:     
Weekly dose, mg   NA 12.5 (10.5 to 12.5)  
Duration, months   NA 36.0 (45.8 to 77.8)  
Prednisolone users/total:   24/32 (75%) 64/67 (95.5%)  
Weekly dose, mg   43.7 (35.0 to 48.7) 35.0 (38.9 to 55.3) 0.167
Duration, months   34.0 (32.6 to 105.8) 48.0 (46.4 to 79.2) 0.180
Salazopyrin, users/total:   26/32 (81.25%) 58/67 (86.56)  
Weekly dose, mg   7,000 (7,882 to 11,233) 7,000 (9,051 to 11,825) 0.395
Duration, months   53.5 (38.8 to 105.1) 50.0 (51.5 to 86.4) 0.848
Hydroxychloroquine:   22/32 (68.75%) 57/67 (85.07%)  
Weekly dose, mg   1,404 (1,404 to 1,968) 1,400 (1,486 to 1,804) 0.241
Duration, months   11.5 (9.2 to 15.7) 13.0 (13.6 to 21.6) 0.644
Celebrex, users/total:   19/32 (59.37) 42/67 (62.68%)  
Weekly dose, mg   1,400 (1,581 to 2,250) 1,400 (1,561 to 2,005) 0.660
Duration, months   18.0 (14.0 to 30.8) 23 (-8.7 to 123.8) 0.829
Meloxicam, users/total:   10/32 (31.3%) 26/67 (38.8%)  
Weekly dose, mg   105 (78.6 to 110.3) 105 (78.8 to 98.8) 0.336
Duration, months   7.5 (0.78 to 23.6) 12.0 (9.6 to 27.4) 0.599
  1. Results are expressed as median (95% CI) (n = 99).
  2. aData were analyzed by Mann-Whitney U test.
  3. ALT = alanine aminotransferase; BMI = body mass index; BP = blood pressure; CRP = C-reactive protein; HAQ = Health Assessment Questionnaire; Hb = hemoglobin; WBC = white blood cells.